PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy
Tel Aviv, Israel – March 16, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022. Ilan Hadar, Chief Executive Officer, stated, “We are pleased to report a number of important […]
PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery
Initial pharmacokinetic data on first 15 patients expected in May 2023 Tel Aviv, Israel – March 14, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has commenced a Phase 3 clinical trial of PRF-110, the Company’s lead […]
PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement
Tel Aviv, Israel – November 15, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced today that on February 7, 2023, it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is eligible for an additional 180 calendar […]
PainReform Provides Business Update for the Third Quarter of 2022
Implements Technology Improvements Related to PRF-110 Manufacturing Process Ahead of Planned Phase 3 Clinical Trial in Bunionectomy Tel Aviv, Israel – November 15, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter ended […]
PainReform Provides Further Update on Manufacturing of PRF-110
TEL AVIV, Israel, Nov. 8, 2022 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a further update related to the manufacturing process of clinical batches for PRF-110. Ilan Hadar, Chief Executive Officer of Pain Reform, stated, “As previously announced, […]
PainReform Provides PRF-110 Manufacturing Update
Completed tech transfer to CMO resulting in new process improvements On track to commence Phase 3 clinical trial in bunionectomy in November 2022 Tel Aviv, Israel – October 4, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided an update […]
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Tel Aviv, Israel – September 1, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September […]
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
Tel Aviv, Israel, August 16, 2022 —PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid price requirement […]
PainReform Provides Business Update for the Second Quarter of 2022
On track to commence Phase 3 clinical trial in bunionectomy in the fourth quarter of 2022 Completes tech transfer to CMO for manufacturing of clinical batches Tel Aviv, Israel – August 16, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today […]
PainReform Provides Business Update for the First Quarter of 2022
Reports successful batch manufacturing of PRF-110 and continued progress towards commencing Phase 3 clinical trials in the second half of 2022 Tel Aviv, Israel – May 17, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, yesterday provided a business update for […]
